Hosted on MSN
(2nd LD) Celltrion acquires U.S. biopharma plant from Eli Lilly to counter tariff threats
SEOUL, Sept. 23 (Yonhap) -- Celltrion Inc., South Korea's leading biopharmaceutical company, said Tuesday its U.S. subsidiary has signed a deal to acquire a U.S. biopharmaceutical production facility, ...
This story is part of Forbes’ coverage of Korea’s Richest 2024. See the full list here. It’s been just over a year since Seo Jung-jin, cofounder of drugmaker Celltrion, came out of his two-year ...
Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for roughly $330 million, the South Korean biosimilar specialist said it will throw down up to 700 billion Korean won ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results